Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Pancreatic Neoplasms 84Carcinoma, Non-Small-Cell Lung 56Triple Negative Breast Neoplasms 35Breast Neoplasms 34Neoplasms 28Neoplasm Metastasis 28Colorectal Neoplasms 17Lung Neoplasms 13Carcinoma, Pancreatic Ductal 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Adenocarcinoma 9Stomach Neoplasms 8Melanoma 8Carcinoma 8Ovarian Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms by Site 6Fallopian Tube Neoplasms 6Small Cell Lung Carcinoma 5Carcinoma, Squamous Cell 5Peritoneal Neoplasms 4Head and Neck Neoplasms 4Digestive System Neoplasms 4Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 3Solid Tumor 3Sarcoma 3Rectal Neoplasms 3Pancreatic Diseases 3Neoplasms by Histologic Type 3

Interventions

seribantumab 2Gemcitabine 2Docetaxel 2130-nm albumin-bound paclitaxel 2patritumab 1Istiratumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Fibromatosis, Gingival, 2 × 130-nm albumin-bound paclitaxel × Clear all
NCT05919537 2025-04-18

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Hummingbird Bioscience

Phase 1 Active not recruiting
68 enrolled
GastrointestinalThoracic

Fibromatosis, Gingival, 2, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Pancreatic Neoplasms

NCT02399137 2018-09-18

CARRIE

Merrimack Pharmaceuticals

Phase 2 Completed
88 enrolled
Gastrointestinal

Fibromatosis, Gingival, 2, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡